Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Colorectal cancer is a leading cause of morbidity and mortality with about 18 000 deaths in the UK and 56 000 in the USA each year. Despite improvements in surgical technique, radiotherapy, and adjuvant chemotherapy, 50% of patients apparently 'cured' by surgery subsequently relapse and die of the disease. There is an obvious need to develop novel rational therapies based on understanding the molecular signatures that separate tumour from normal colorectal epithelium.

Type

Journal article

Journal

Lancet Oncol

Publication Date

11/2000

Volume

1

Pages

159 - 168

Keywords

Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antigens, Neoplasm, Clinical Trials as Topic, Colorectal Neoplasms, Cytotoxicity, Immunologic, Humans, Immunity, Cellular, Immunization, Passive, Immunotherapy, Active, Immunotherapy, Adoptive, Prodrugs, Research Design, Vaccination